@curator

1 month ago

Article

Intrathecal delivery of adipose-derived mesenchymal stem cells in traumatic spinal cord injury: Phase I trial - Nature Communications

Rating: 0.0

Likes: 1

Library: 1

Intrathecal delivery of adipose-derived mesenchymal stem cells in traumatic spinal cord injury: Phase I trial - Nature Communications

Intrathecal delivery of autologous culture-expanded adipose tissue-derived mesenchymal stem cells (AD-MSC) could be utilized to treat traumatic spinal cord injury (SCI). This Phase I trial (ClinicalTrials.gov: NCT03308565) included 10 patients with American Spinal Injury Association Impairment Scale (AIS) grade A or B at the time of injury. The study's primary outcome was the safety profile, as captured by the nature and frequency of adverse events.

Rate This Post

Rate The Educational Value

Rate The Ease of Understanding and Presentation

Interesting or Boring? Rate the Entertainment Value

Intrathecal delivery of adipose-derived mesenchymal stem cells in traumatic spinal cord injury: Phase I trial - Nature Communications

Rate This Post

Related Topics

Comments

Media:

My Account:

Boostlane:

Select a Category

Topics Trending Today

Recommended Media

Boostlane Reward System

Unlocking the Power of Knowledge
for Humanity's Progress

Quick Links

Select a Locale

Unlocking the Power of Knowledge
for Humanity's Progress

Intrathecal delivery of adipose-derived mesenchymal stem cells in traumatic spinal cord injury: Phase I trial - Nature Communications

Rate This Post

Related Topics

Comments

Media:

My Account:

Boostlane:

Select a Category

Topics Trending Today

Recommended Media

Boostlane Reward System

Unlocking the Power of Knowledge for Humanity's Progress

Quick Links

Select a Locale

Unlocking the Power of Knowledge for Humanity's Progress

Unlocking the Power of Knowledge
for Humanity's Progress

Unlocking the Power of Knowledge
for Humanity's Progress